key: cord-0725107-579aqcel
authors: Kohli-Pamnani, Anita; Zapata, Kristen; Gibson, Tiffany; Kwittken, Pamela L.
title: Coronavirus disease 2019 messenger RNA vaccine skin tests and serum histamine levels in allergic reactions
date: 2022-02-22
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.12.014
sha: 1a994838c3ea0e9b45fdf6e7ece0477182227d9c
doc_id: 725107
cord_uid: 579aqcel

nan

the suggestion that antihistamine premedication may prevent some allergic reactions. 3 Most patients will tolerate subsequent vaccination with the mRNA COVID-19 vaccine with or without premedication. [1] [2] [3] [4] [5] [6] [7] In the report of de Chaisemartin et al, 1 3 of 5 patients tolerated their consequent COVID-19 mRNA vaccine. Furthermore, 1 patient already received their second dose to which anaphylaxis had occurred. In addition, 1 patient passed away from unrelated cause before the receipt of vaccine dose 2. In our case series, 95% (n = 37) tolerated their succeeding COVID-19 vaccine without serious allergic reaction. Moreover, 92% (n = 36) received 2 doses of their COVID-19 vaccines. Of the patients who tolerated their subsequent mRNA vaccines, 62% received premedication, which could include H 1 and H 2 antihistamines and leukotriene inhibitors.

A potential explanation of transiently elevated serum histamine levels in the patient described by de Chaisemartin et al 1 could be basophil activation. Warren et al 8 revealed that 11 patients with anaphylactic reactions to the COVID-19 mRNA vaccine had negative skin test results to the vaccine and excipients. Nevertheless, most had positive basophil activation test results to PEG. All had positive basophil activation test results to the mRNA vaccine. Notably, PEG immunoglobulin G was found despite undetectable PEG immunoglobulin E in the tested patients with allergic reactions.

In summary, de Chaisemartin et al 1 raise an interesting point on possible transient elevation of serum histamine levels. Further research is necessary to characterize skin tests with the specific vaccines and biomarkers such as serum histamine levels to evaluate which endotypes of post−COVID-19 mRNA vaccine allergic reactions may benefit from premedication or desensitization to COVID-19 mRNA vaccines.

Immune parameters during anaphylaxis to mRNA COVID-19 vaccines: not the usual suspects?

Coronavirus disease 2019 vaccine hypersensitivity evaluated with vaccine and excipient allergy skin testing

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy

Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose

First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing

Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience

Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination

Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system